Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
181 participants
INTERVENTIONAL
2019-10-10
2020-05-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DMT310-009 Topical in the Treatment of Acne Vulgaris
NCT06090721
DMT310-001 Topical in the Treatment of Acne Vulgaris
NCT03536637
DMT310-005 Topical in the Treatment of Acne Rosacea
NCT05108025
DMT210 Topical Gel in the Treatment of Acne Rosacea
NCT03003104
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study Treatment 1
DMT310 Powder mixed with Hydrogen Peroxide
DMT310
Topical Powder
Study Treatment 2
Placebo powder mixed with Hydrogen Peroxide
Placebo
Placebo Topical Powder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DMT310
Topical Powder
Placebo
Placebo Topical Powder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of moderate to severe acne vulgaris as determined by:
Investigator's Global Assessment (IGA) at Randomization Patient has at least 20 inflammatory lesions on the face Patient has at least 20 noninflammatory lesions on the face
* Patient is willing to apply the Investigational Product as directed
* Patient is willing and able to comply with the protocol
Exclusion Criteria
* Patient is taking a topical therapy on the face which may affect the patient's acne
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dermata Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermata Investigational Site
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DMT310-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.